An analysis of perioperative surgical mortality and morbidity in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study.
OBJECTIVE
Our aim was to determine the perioperative morbidity and mortality rates of patients in the surgical arm of the multi-institutional, prospective, randomized Asymptomatic Carotid Atherosclerosis Study (ACAS).


METHODS
Of 828 patients with carotid stenosis of 60% or more randomized to the surgical arm of ACAS, 721 underwent carotid endarterectomy (CEA). To qualify for participation, surgeons were required to have performed at least 12 CEAs per year with a combined neurological morbidity and mortality rate no greater than 3% for asymptomatic patients and 5% for symptomatic patients. Clinical centers had to demonstrate arteriographic morbidity less than 1% and mortality less than 0.1% per year. Primary events were stroke and death in the period between randomization and 30 days after surgery; secondary events were transient ischemic attack and myocardial infarction occurring in the same period.


RESULTS
Of the 721 patients who underwent CEA, 1 died and 10 others had strokes within 30 days (1.5%). Of the 415 who underwent arteriography after randomization but before CEA, 5 (1.2%) suffered transient ischemic attack or stroke caused by arteriography. Thus, a nearly equal risk of stroke was associated with both CEA and carotid arteriography. In addition, 6 transient ischemic attacks and 3 myocardial infarctions could be directly linked to CEA, for a total CEA event rate of 2.6%.


CONCLUSIONS
Patients with asymptomatic internal carotid artery stenosis exceeding 60% reduction in diameter who are acceptable candidates for elective operation may be considered for CEA if the combined arteriographic and surgical complication rates are 3% or less.
Young
B
B
Albert B. Chandler Medical Center, Lexington, Ky, USA.
Moore
W S
WS
Robertson
J T
JT
Toole
J F
JF
Ernst
C B
CB
Cohen
S N
SN
Broderick
J P
JP
Dempsey
R J
RJ
Hosking
J D
JD
D000758:Anesthesia; D001161:Arteriosclerosis / Q000401:mortality / Q000601:surgery*; D001241:Aspirin / Q000627:therapeutic use; D016893:Carotid Stenosis / Q000401:mortality / Q000601:surgery*; D002544:Cerebral Infarction / Q000401:mortality / Q000517:prevention & control*; D003131:Combined Modality Therapy; D003391:Cranial Nerves / Q000503:physiopathology; D003645:Death, Sudden / Q000453:epidemiology; D003922:Diabetes Mellitus, Type 1 / Q000453:epidemiology; D017558:Elective Surgical Procedures / Q000401:mortality; D016894:Endarterectomy, Carotid / Q000401:mortality; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D002546:Ischemic Attack, Transient / Q000453:epidemiology / Q000517:prevention & control*; D009203:Myocardial Infarction / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D011183:Postoperative Complications / Q000401:mortality*; D011446:Prospective Studies; D012907:Smoking / Q000453:epidemiology; D013695:Temperance / Q000706:statistics & numerical data
D001241:Aspirin